ADRA2C
Alpha-2C adrenergic receptor
As of the edition of 20 October 2026, ADRA2C (alpha-2C adrenergic receptor, UniProt P18825) has 41 drugs tested at it and 39 companies on the list, 1 on route A and 17 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P18825
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Lungs and airways; Eye; Cancer; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 2,193
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 35 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 41 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dexmedetomidine | Marketed | Phase 4 | none listed |
| Epinephrine | Marketed | Phase 4 | none listed |
| Norepinephrine | Marketed | Phase 4 | none listed |
| Clonidine | Marketed | Phase 4 | none listed |
| Brimonidine | Marketed | Phase 4 | none listed |
| Guanfacine | Marketed | Phase 4 | none listed |
| Mirtazapine | Marketed | Phase 4 | none listed |
| Oxymetazoline | Marketed | Phase 4 | none listed |
| Ephedrine | Marketed | Phase 4 | none listed |
| Labetalol | Marketed | Phase 4 | none listed |
| Droxidopa | Marketed | Phase 4 | none listed |
| Lofexidine | Marketed | Phase 4 | none listed |
12 of 41 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 17 |
| Engaged | 8 |
| Undetermined | 13 |
| Total on the list | 39 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Pfizer | Route B |
| Legacy Pharma Inc Sezc | Route B |
The other 36 companies at ADRA2C
In the product39 companies in all; 36 are not named here, and no score is.
See the 39 companies at ADRA2C, ranked, with the facts behind eachRequest access. Nothing is shown until you do.